Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Hanover – page 38

637 clinical trials in Hanover, Germany across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Hanover at a glance
637
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

637 trials in Hanover

Open in trial search

Cystic fibrosis

Not recruiting

Study on the Safety and Tolerability of Elexacaftor, Tezacaftor, and Ivacaftor in Children with Cystic Fibrosis Aged 12 to Less Than 24 Months

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Elexacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Chronic hepatitis B

Not recruiting

Study on Bepirovirsen for Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue Treatment

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bepirovirsen
  • Sponsor:Glaxosmithkline Research & Development Limited

Dermatitis atopic

Not recruiting

Study on Tralokinumab for Moderate-to-Severe Atopic Hand Eczema in Patients Needing Systemic Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tralokinumab
  • Sponsor:Leo Pharma A/S

Squamous cell carcinoma of head and neck

Not recruiting

Study of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and Pembrolizumab for Patients with Advanced Head and Neck Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Acp-017
  • Sponsor:Ascendis Pharma Oncology Division A/S

Alagille syndrome

Not recruiting

Long-term Study on the Safety and Effectiveness of Odevixibat for Patients with Alagille Syndrome

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Odevixibat
  • Sponsor:Ipsen Pharma

Malignant melanoma stage IV+1

Not recruiting

Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Chronic kidney disease

Not recruiting

Study on Dapagliflozin for Patients with Severe Chronic Kidney Disease to Improve Kidney and Heart Health Outcomes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Universitair Medisch Centrum Groningen

Pulmonary arterial hypertension

Not recruiting

Study on the Safety and Effectiveness of Cibotercept (KER-012) with Other Drugs for Adults with Pulmonary Arterial Hypertension

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cibotercept
  • Sponsor:Keros Therapeutics Inc.

Multiple sclerosis+1

Not recruiting

Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer+2

Not recruiting

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Luspatercept for Patients with Lower-risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:Celgene Corp.

Non-small cell lung cancer

Not recruiting

Study on Durvalumab with Oleclumab or Monalizumab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Hanover

What the registry says about research in the country

01 Respiratory Diseases

Clinical trials focusing on respiratory infections and conditions, including studies of vaccines against RSV and human metapneumovirus in older adults. Research also includes treatment evaluation for chronic obstructive pulmonary disease.

  • RSV vaccine development
  • COPD treatment innovations
  • Viral respiratory infections

Multiple studies are evaluating novel therapeutic approaches for both acute and chronic respiratory conditions.

02 Oncology Research

Innovative trials in cancer treatment, including studies for bladder cancer, multiple myeloma, and advanced breast cancer. Research focuses on combination therapies and novel treatment approaches.

  • Immunotherapy combinations
  • Blood cancer treatments
  • Targeted therapies

Studies emphasize personalized treatment approaches and immune system-based therapies.

03 Neurological Conditions

Research focusing on neurodegenerative diseases, particularly Alzheimer's Disease and Amyotrophic Lateral Sclerosis. Studies evaluate new diagnostic tools and therapeutic interventions.

  • Early-stage dementia treatment
  • ALS therapeutic development
  • Brain clearance mechanisms

Trials aim to address both symptomatic treatment and disease progression.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.